Subscribe
Israel-Hamas Conflict
US Politics
Hurricanes
Republican Party
Donald Trump
US Presidential Election
Election Day
Fox News
US Economy
Kamala Harris
US Crime
Halloween
NFL
Published

European watchdog sees nothing in Alzheimer's drug: 'Too high risk of side effects.'

Summary by rd.nl
A potential cure for Alzheimer's disease is unlikely to be on the market for the time being. A committee of the European regulator, the European Medicines Agency (EMA), recommends rejecting the drug Lecanemab. The final decision is up to the European Commission, but it usually takes over the advice of the Amsterdam-based watchdog.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

AlzheimerAlzheimer
Alzheimer's DiseaseAlzheimer's Disease
NetherlandsNetherlands

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal